PALI PALISADE BIO, INC. Insider Trading

Director Robert Jr. Baltera buys 30,000 shares at $1.98 across 2 transactions totaling $59,400.00

Robert Jr. Baltera, a Director at Palisade Bio, purchased 30,000 shares (30.0K shares) for $59,400.00 ($59.4K) across two separate transactions on 2026-07-01 and 2026-07-02 at a blended average price of $1.98. His holdings increased from 336,904 shares (336.9K shares) to 366,904 shares (366.9K shares), representing a net change of purchased 30,000 shares (+8.9% vs pre-transaction holdings). The company is unprofitable, with a net income of $-9,600,000.00 ($-9.6M) and zero revenue in its latest quarter, operating in a financially stressed posture. The stock trades at $2.04 currently, down -28.7% from its 52-week high of $2.86, though it has recovered +17.2% over the past 30 days and +6.8% over the past 90 days, suggesting recent volatility and partial recovery.

Director Williams bought 5.0K shares of PALI at $1.67 on 2026-01-16, doubling holdings to 10.7K; stock now -30.0% from 52-week high.

Director Williams Donald Allen purchased 5,000 shares at $1.67 on 2026-01-16, increasing his stake by 87.3% to 10.7K shares post-transaction. This buy follows a transaction just one week prior (2026-01-09) at the same ticker and comes as the stock trades 30.0% below its 52-week high of $2.50 and 15.9% lower over the past 30 days. His same-ticker history shows mixed outcomes: two prior buys generated exceptional 90-day returns (+911.6% and +1403.1%), but the most recent measurable PALI trade (2024-05-28) resulted in a -29.3% 90-day loss, indicating inconsistent timing accuracy at this specific security. The company is unprofitable with -$2.9M net income and zero revenue in the latest quarter, presenting material execution risk alongside the price deterioration and rapid succession of purchases.

Director Donald Allen buys 5,000 shares of PALI at $1.88, expanding stake 686.8%; company unprofitable with -$2.9M net income.

Director Williams Donald Allen purchased 5,000 shares at $1.88, substantially expanding his PALI holdings from 728 to 5,728 shares—a 686.8% increase. His prior two buys at this ticker demonstrated strong 90-day returns (+911.6% and +1403.1%), though one earlier purchase resulted in a -29.3% 90-day decline, indicating mixed execution at this specific ticker. Against this backdrop, the company's fundamentals show revenue of $0.00 in the latest quarter and a full-year net income of -$2.9M, with annual revenue growth of -100.0%, presenting a distressed operational picture. The current stock price of $1.89 sits -24.4% from its 52-week high and reflects a -2.6% 30-day decline, yet the insider chose to deploy capital aggressively at this juncture. This substantial accumulation by a director at a fundamentally challenged biotech warrants close investor scrutiny of both the strategic rationale and near-term catalysts that may have prompted the commitment.